Your browser is no longer supported. Please, upgrade your browser.
Settings
IDYA [NASD]
IDEAYA Biosciences, Inc.
Index- P/E- EPS (ttm)-1.22 Insider Own0.30% Shs Outstand31.76M Perf Week11.72%
Market Cap934.67M Forward P/E- EPS next Y-1.62 Insider Trans-45.72% Shs Float19.55M Perf Month16.72%
Income-31.50M PEG- EPS next Q-0.15 Inst Own61.30% Short Float9.69% Perf Quarter19.22%
Sales26.80M P/S34.88 EPS this Y58.50% Inst Trans-2.25% Short Ratio8.45 Perf Half Y39.36%
Book/sh7.34 P/B3.34 EPS next Y-45.90% ROA-11.30% Target Price31.56 Perf Year116.81%
Cash/sh7.93 P/C3.09 EPS next 5Y- ROE-15.80% 52W Range10.90 - 26.00 Perf YTD75.00%
Dividend- P/FCF- EPS past 5Y- ROI-17.80% 52W High-5.77% Beta-
Dividend %- Quick Ratio8.50 Sales past 5Y- Gross Margin- 52W Low124.77% ATR1.69
Employees69 Current Ratio8.50 Sales Q/Q- Oper. Margin- RSI (14)67.13 Volatility10.52% 8.50%
OptionableYes Debt/Eq0.00 EPS Q/Q52.20% Profit Margin- Rel Volume0.98 Prev Close23.49
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume224.09K Price24.50
Recom1.40 SMA2018.84% SMA5017.14% SMA20034.51% Volume220,095 Change4.30%
Jun-04-21Resumed Robert W. Baird Outperform $28
Mar-11-21Initiated Guggenheim Buy $32
Oct-07-20Initiated Wedbush Outperform $21
Sep-01-20Initiated Northland Capital Outperform $28
Jul-13-20Upgrade JP Morgan Neutral → Overweight $28
Jun-17-20Reiterated H.C. Wainwright Buy $13 → $22
Apr-06-20Initiated H.C. Wainwright Buy $13
Mar-13-20Initiated ROTH Capital Buy $12
Oct-17-19Initiated Oppenheimer Outperform $17
Sep-10-19Initiated Robert W. Baird Outperform
Jun-17-19Initiated JP Morgan Neutral $15
Jun-17-19Initiated Jefferies Buy $14
Jun-17-19Initiated Citigroup Buy $20
Jul-12-21 04:11PM  
Jul-08-21 06:39AM  
Jul-07-21 09:29PM  
08:01AM  
Jul-06-21 04:01PM  
Jun-28-21 06:00AM  
May-24-21 06:01AM  
May-16-21 05:21AM  
May-10-21 07:30AM  
06:00AM  
06:00AM  
May-06-21 06:00AM  
Apr-19-21 06:00AM  
Apr-18-21 08:30AM  
Apr-16-21 06:00AM  
Apr-15-21 04:01PM  
06:00AM  
Mar-23-21 10:24AM  
07:30AM  
06:05AM  
06:05AM  
Mar-11-21 06:00AM  
Mar-01-21 06:00AM  
Feb-22-21 06:00AM  
Feb-17-21 06:00AM  
Feb-15-21 01:12AM  
Feb-08-21 06:00AM  
Feb-01-21 06:00AM  
Jan-19-21 06:00AM  
Jan-11-21 06:00AM  
Jan-05-21 06:00AM  
Jan-04-21 06:00AM  
Dec-14-20 06:00AM  
Dec-11-20 10:23PM  
Dec-08-20 12:43PM  
Nov-16-20 11:19PM  
Nov-15-20 08:50AM  
Nov-12-20 06:00AM  
Nov-02-20 06:00AM  
Oct-22-20 06:00AM  
Sep-24-20 08:15AM  
06:00AM  
Sep-04-20 12:52PM  
Sep-02-20 06:21PM  
Aug-31-20 06:00AM  
Aug-19-20 01:33PM  
Aug-12-20 07:30AM  
06:00AM  
Aug-07-20 08:33AM  
Aug-05-20 04:21PM  
Aug-04-20 06:00AM  
Jul-16-20 06:00AM  
Jul-14-20 06:00AM  
Jul-09-20 06:00AM  
Jun-30-20 06:00AM  
Jun-22-20 04:35PM  
Jun-17-20 09:34PM  
09:53AM  
Jun-16-20 04:01PM  
10:54AM  
08:13AM  
06:00AM  
Jun-12-20 12:05PM  
Jun-11-20 06:00AM  
Jun-09-20 08:58AM  
Jun-08-20 06:00AM  
May-24-20 07:00AM  
May-19-20 06:00AM  
May-15-20 06:00AM  
May-12-20 06:00AM  
Apr-21-20 06:00AM  
Mar-24-20 06:00AM  
Mar-18-20 06:00AM  
06:00AM  
Mar-11-20 06:00AM  
Feb-19-20 08:19AM  
Jan-15-20 06:00AM  
Jan-10-20 06:00AM  
Jan-06-20 06:00AM  
Dec-26-19 10:48AM  
Dec-19-19 06:30PM  
Dec-18-19 06:00AM  
Dec-16-19 07:44AM  
Dec-09-19 06:00AM  
Nov-25-19 08:58AM  
Nov-20-19 06:00AM  
Nov-15-19 06:00AM  
Nov-13-19 06:00AM  
Nov-05-19 06:00AM  
Nov-01-19 07:38AM  
Oct-31-19 04:01PM  
Oct-25-19 06:00AM  
Aug-23-19 11:40AM  
Aug-12-19 04:01PM  
Jul-09-19 10:07AM  
06:00AM  
Jul-01-19 02:08PM  
Jun-17-19 10:08AM  
May-28-19 01:03PM  
May-23-19 01:21PM  
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients with solid tumors having MTAP deletions; PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Throne JasonSVP, General CounselJul 27Option Exercise13.3410,000133,40010,000Jul 29 05:17 PM
Dillon Michael P.SVP, Chief Scientific OfficerJul 27Option Exercise5.6210,00056,150108,789Jul 29 05:18 PM
Throne JasonSVP, General CounselJul 27Sale25.1710,000251,6830Jul 29 05:17 PM
Dillon Michael P.SVP, Chief Scientific OfficerJul 27Sale25.1510,000251,46098,789Jul 29 05:18 PM
Throne JasonSVP, General CounselJul 06Option Exercise8.5210,00085,22910,000Jul 08 07:00 PM
Dillon Michael P.SVP, Chief Scientific OfficerJul 06Option Exercise6.921,50010,380100,289Jul 08 07:01 PM
Throne JasonSVP, General CounselJul 06Sale22.2410,000222,4080Jul 08 07:00 PM
Dillon Michael P.SVP, Chief Scientific OfficerJul 06Sale22.241,50033,35898,789Jul 08 07:01 PM
Dillon Michael P.SVP, Chief Scientific OfficerJun 17Option Exercise6.923,89326,940102,682Jun 17 08:59 PM
Dillon Michael P.SVP, Chief Scientific OfficerJun 17Sale22.493,89387,54098,789Jun 17 08:59 PM
Dillon Michael P.SVP, Chief Scientific OfficerJun 16Option Exercise6.921,1077,66099,896Jun 17 08:59 PM
Dillon Michael P.SVP, Chief Scientific OfficerJun 16Sale22.471,10724,87398,789Jun 17 08:59 PM
Dillon Michael P.SVP, Chief Scientific OfficerJun 07Option Exercise6.921,50010,380100,289Jun 09 06:12 PM
Dillon Michael P.SVP, Chief Scientific OfficerJun 07Sale20.221,50030,33398,789Jun 09 06:12 PM
Dillon Michael P.SVP, Chief Scientific OfficerMay 11Option Exercise6.925,00034,600103,789May 13 05:08 PM
Dillon Michael P.SVP, Chief Scientific OfficerMay 11Sale20.225,000101,09298,789May 13 05:08 PM
Lackner MarkSVP, Head of BiologyFeb 10Option Exercise6.985964,160596Feb 10 06:53 PM
Lackner MarkSVP, Head of BiologyFeb 10Sale21.0059612,5160Feb 10 06:53 PM
Lackner MarkSVP, Head of BiologyFeb 09Option Exercise6.981,1047,7061,104Feb 10 06:53 PM
Dillon Michael P.SVP, Chief Scientific OfficerFeb 09Option Exercise6.925,00034,600103,789Feb 10 07:31 PM
Dillon Michael P.SVP, Chief Scientific OfficerFeb 09Sale20.745,000103,69698,789Feb 10 07:31 PM
Lackner MarkSVP, Head of BiologyFeb 09Sale21.051,10423,2340Feb 10 06:53 PM
Lackner MarkSVP, Head of BiologyFeb 08Option Exercise6.983002,094300Feb 10 06:53 PM
Lackner MarkSVP, Head of BiologyFeb 08Sale21.013006,3020Feb 10 06:53 PM
BVF PARTNERS L P/ILSee Explanation of ResponsesFeb 02Sale18.0046,409835,362233,150Feb 04 05:15 PM
Lackner MarkSVP, Head of BiologyJan 26Option Exercise6.391,5009,5802,501Jan 28 04:59 PM
Lackner MarkSVP, Head of BiologyJan 26Sale18.462,50146,1580Jan 28 04:59 PM
Hata Yujiro SPresident and CEODec 22Option Exercise4.318,00034,480666,286Dec 23 04:06 PM
Dillon Michael P.SVP, Chief Scientific OfficerDec 18Option Exercise4.317,75033,40298,789Dec 22 05:35 PM
Throne JasonSVP, General CounselDec 04Sale15.371,97930,4100Dec 08 04:03 PM
5AM Ventures IV, L.P.Former 10% holderNov 11Sale13.66800,00010,928,00091,142Nov 13 08:53 PM